+22.5%
KORU vs MRNA
+153.9%
-131.4%
-92.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -25.0% | -2.2% | -22.9% | -24.7% |
| 7D | -38.0% | -12.7% | -25.3% | -36.5% |
| 30D | -60.1% | -20.7% | -39.5% | -58.2% |
| 3M | -76.6% | +46.3% | -122.9% | -77.7% |
| 6M | -87.5% | +305.2% | -392.7% | -91.8% |
| YTD | -47.6% | +561.2% | -608.8% | -69.9% |
| 1Y | -27.8% | +772.1% | -799.9% | -62.3% |
| 3Y | +22.5% | +147.0% | -124.4% | -16.9% |
| All | +22.5% | +153.9% | -131.4% | -16.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling